SOURCE: Market Pulse

June 24, 2009 08:30 ET

Market Pulse Breaking News Alert for Wednesday, June 24, 2009: ARYC -- Mark Schena, PhD, Positions Arrayit Corporation to Enter Molecular Diagnostics Using VIP™ Technology!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - June 24, 2009) - Market Pulse News Alert for this AM, Stocks to Watch are: Arrayit Corporation (OTCBB: ARYC), Monogram Biosciences Inc. (NASDAQ: MGRM), Boston Scientific Corporation (NYSE: BSX) and mPhase Technologies Inc. (OTCBB: XDSL).

Investors need to be watching Arrayit Corporation (OTCBB: ARYC) this AM! Arrayit Corporation is engaged in the development, manufacture, and marketing of life science technologies and integrated systems for the analysis of genetic variation, biological function, and diagnostics. Arrayit offers a product line of approximately 650 tools to 2,500 laboratories worldwide. The company's products include microarrayers, microarray scanners, DNA and protein microarrays, microarray printing, microarray substrates and slides, microarray instruments, amplification and labeling, purification kits, microarray hardware, buffers and solutions, microarray cleanrooms, books and software, CGH microarrays, and microarray platforms. Arrayit's worldwide business position leverages the company's widely used patented microarray manufacturing platform and revolutionary VIP™ genotyping technology. Nearly every major research center in the world uses Arrayit products including research laboratories, pharmaceutical companies, universities, biotechnology companies, hospitals, government agencies, and nonprofit research organizations. The company is also involved in the import, export, and distribution of industrial and food grade chemicals for plastics, fertilizers, and green energy applications. It has research collaboration with The Parkinson's Institute of Sunnyvale to discover biomarkers for Parkinson's disease. ARYC recently announced that it is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus. The 2009 swine flu outbreak has raised concerns at the CDC and the World Health Organization (WHO). The CDC and WHO believe that the current outbreak poses a pandemic risk because the H1N1 flu virus contains genetic elements from both the swine and human influenza viruses, allowing direct human-to-human transmission without the need for agricultural contact. Arrayit is an exciting and innovative public company that strives to increase shareholder equity by inventing, developing, manufacturing and supplying sophisticated life sciences products and services to an extensive customer base spanning 50 countries. Arrayit is a leader in the field of molecular diagnostics with patented technology that allows the screening and monitoring of up to 80,000 patient samples on a single microscope slide, rather than testing one patient per slide as is currently practiced. Their corporate philosophy is embodied by a highly skilled, multidisciplinary team of investors, business professionals, scientists, engineers and executive and support staff who place shareholder value, product quality, customer service and price competitiveness as their highest priorities. Arrayit empowers decisive strategic advantage and large return on investment for their customers in the research, pharmaceutical, diagnostic, and health care markets! ARYC just had excellent news out in a press release before today's opening bell announcing that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP™), is ready for manufacture and distribution! The company also said that the single laboratory test can screen up to 100,000 patients! This could be great news for investors!

Arrayit Corporation (OTCBB: ARYC), a leading manufacturer of products and services for disease prevention, treatment and cure, announced today that its microarray-based diagnostic test, patented under the trade name Variation Identification Platform (VIP™), is ready for manufacture and distribution.

Created by microarray pioneer and Arrayit President, Dr. Mark Schena, VIP is the world's key microarray diagnostics patent that allows clinicians to test up to 100,000 patients against a single disease state health condition, print that bio-information on a single slide, and draw a diagnosis for each individual patient. Arrayit is now positioned to move this revolutionary technology from research to clinical applications and beyond.

In 1995, Dr. Schena and colleagues published the first paper on microarrays in the premier scientific journal, Science, introducing microarrays to the world as a new scientific technology. His work rapidly led to a new field of discovery that uses microarrays to investigate both genes and proteins in research and diagnostics. Acknowledged by his peers for the importance of these accomplishments, Dr. Schena was proclaimed the Father of Microarray Technology by The Scientist, a broadly read scientific journal, in 2003.

Today microarrays are used in more than 100,000 laboratories in 50 countries to explore complicated questions in biology, chemistry, agriculture and medicine. The microarray field to date has produced 550,000 scientific publications. The commercial expansion of microarray technologies has created a multi-billion dollar research market with over 200 companies that produce ancillary products and services.

Dr. Schena has authored five foundational books and has published more than 30 important papers. Dr. Schena has organized symposia and course work, chaired societal meetings and promoted the expansion of microarray technology -- accruing over half million travel miles to speak to audiences of PhD's, MD's and life science professionals.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit for more information.

Stocks in the news and acting well as of late include: Monogram Biosciences Inc. (NASDAQ: MGRM), Boston Scientific Corporation (NYSE: BSX) and mPhase Technologies Inc. (OTCBB: XDSL).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis.

Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated, in connection with its profile of Arrayit Corporation, fifty thousand shares of Arrayit Corporation's common stock by a third party shareholder. Additionally, MP bought for its own account in the open market, forty thousand shares of Arrayit Corporation's shares for a total purchase price of twenty three thousand eight hundred twenty dollars. To date, MP has not sold any of these shares. When MP receives shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information